Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Autolus is a biopharmaceutical company focused on T-cell programming and manufacturing technology.
Clearside BioMedical is an ophthalmic company that specializes in the research, development, and commercialization of therapeutic products.
Chroma Medicine is a biotechnology company that develops genetic medicines for the treatment of genetic disorders.
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
Arkuda Therapeutics is a pharmaceutical company.
Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
Ensomaa is a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications.
Tioga Cardiovascular is a healthcare company providing valve replacement solutions for mitral and tricuspid applications.
Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
858 Therapeutics develops small molecule drugs targeting oncology and immunology.
GC Therapeutics uses synthetic biology to program patient-derived stem cells into various cell types in an efficient and scalable manner.
Moximed develops innovative therapies for patients with knee osteoarthritis.
Adona Medical is a technology-based company that designs and develops heart failure management systems to improve heart care.
Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas.
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders.
BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3K malignancies.
Synnovation Therapeutics is a precision oncology company that develops therapeutics that aims to help people with cancer.
Nexo Therapeutics offers treatments for some of cancer's most intractable targets.
Expansion Therapeutics is a biotechnology company focusing on developing transformative oral medicines for severe RNA-mediated diseases.
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways.
Cormorant Asset Management has invested in 205 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Cormorant Asset Management's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Life Science. The firm invests across 11 different industry categories.
Among tracked funding rounds, Autolus received $350.0M in a Post-IPO Equity round. Cormorant Asset Management's total known invested capital is $20.8B.
Cormorant Asset Management's average investment size is $136.8M across its portfolio of 205 companies.
Recent Cormorant Asset Management portfolio additions include Autolus, Clearside Biomedical, Chroma Medicine, Tyra Biosciences, ADARx Pharmaceuticals. These companies were founded in 2020 or later.